Top 7 Epilepsy treatments startups in USA
May 10, 2026
|
Like
25
1
Funding: $440.1M
Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
Neurona Therapeutics develops cell therapies for neurological disorders, focusing on treatments like NRTX-1001 for epilepsy.
2
Funding: $573.1M
Praxis is a clinical-stage genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders
Praxis is a clinical-stage genetic neuroscience company that develops high-impact therapies for patients and families affected by complex and debilitating brain disorders
3
Funding: $457.1M
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
NeuroPace develops and markets implantable devices for the treatment of neurological disorders.
4
Funding: $260M
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
Neurocrine Biosciences engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases.
5
Funding: $135.5M
QurAlis specializes in developing and developing precision therapies for amyotrophic lateral sclerosis (ALS), based on its recent breakthrough discovery of the links between STATHMIN-2 and TDP-43. Company's lead therapeutics are QRL-201 - first-in-class molecule for the treatment of ALS that targets STMN2 expression in ALS patients, and QRL-101 - potential best-in-class selective activator of the Kv7.2/7.3 ion channel for the treatment of disease progression caused by hyperexcitability in ALS, as well as for the treatment of epilepsy and pain. Beyond ALS, QurAlis is developing a robust precision medicine portfolio for the treatment of neurodegenerative and neurological diseases, such as epilepsy, pain, frontotemporal dementia, fragile X syndrome, and progressive supranuclear palsy.
QurAlis specializes in developing and developing precision therapies for amyotrophic lateral sclerosis (ALS), based on its recent breakthrough discovery of the links between STATHMIN-2 and TDP-43. Company's lead therapeutics are QRL-201 - first-in-class molecule for the treatment of ALS that targets STMN2 expression in ALS patients, and QRL-101 - potential best-in-class selective activator of the Kv7.2/7.3 ion channel for the treatment of disease progression caused by hyperexcitability in ALS, as well as for the treatment of epilepsy and pain. Beyond ALS, QurAlis is developing a robust precision medicine portfolio for the treatment of neurodegenerative and neurological diseases, such as epilepsy, pain, frontotemporal dementia, fragile X syndrome, and progressive supranuclear palsy.
6
Funding: $54.4M
Zeto is transforming EEG for hospitals with a wireless, zero-prep, dry electrode headset backed by a state-of-the-art cloud platform
Zeto is transforming EEG for hospitals with a wireless, zero-prep, dry electrode headset backed by a state-of-the-art cloud platform
7
Funding: $18.4M
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
NeuroSigma is a life sciences company focused on bioelectronics products and commercialization of its unique Trigeminal Nerve Stimulation (TNS) technology, and has a growing pipeline of treatments targeting epilepsy, depression, attention deficit hyperactivity disorder (ADHD), post-traumatic stress disorder (PTSD), Lennox Gastaut syndrome (LGS) and traumatic brain injury (TBI).
★
See also:
